{
    "ticker": "PFTAU",
    "name": "Profectus BioSciences, Inc.",
    "description": "Profectus BioSciences, Inc. is a biotechnology company focused on the development of innovative solutions for infectious diseases and cancer therapies. Founded with the goal of addressing significant unmet medical needs, Profectus leverages its proprietary platform technologies to create a range of therapeutic candidates, including vaccines and immunotherapies. The company is particularly recognized for its advancements in the field of viral vaccine development, including its work on vaccines for HIV and other viral infections. Profectus is committed to scientific excellence and collaborates with leading academic institutions and research organizations to enhance its research capabilities and accelerate the development of its product pipeline. The company aims to transform the treatment landscape for patients through groundbreaking therapies that harness the power of the immune system. With a strong emphasis on safety and efficacy, Profectus is dedicated to bringing novel therapeutic options from the laboratory to the clinic, making a meaningful impact on global health.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Baltimore, Maryland, USA",
    "founded": "2002",
    "website": "https://www.profectusbio.com",
    "ceo": "Dr. John Doe",
    "social_media": {
        "twitter": "https://twitter.com/ProfectusBio",
        "linkedin": "https://www.linkedin.com/company/profectus-biosciences/"
    },
    "investor_relations": "https://www.profectusbio.com/investor-relations",
    "key_executives": [
        {
            "name": "Dr. John Doe",
            "position": "CEO"
        },
        {
            "name": "Jane Smith",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Vaccines",
            "products": [
                "HIV Vaccine",
                "Vaccine for Infectious Diseases"
            ]
        },
        {
            "category": "Immunotherapies",
            "products": [
                "Cancer Immunotherapy"
            ]
        }
    ],
    "seo": {
        "meta_title": "Profectus BioSciences, Inc. | Innovative Biotech Solutions",
        "meta_description": "Explore Profectus BioSciences, Inc., a leader in biotechnology developing vaccines and immunotherapies for infectious diseases and cancer. Learn about our pipeline and commitment to global health.",
        "keywords": [
            "Profectus BioSciences",
            "Biotechnology",
            "Vaccines",
            "Immunotherapy",
            "Infectious Diseases",
            "Cancer Therapies"
        ]
    },
    "faq": [
        {
            "question": "What does Profectus BioSciences focus on?",
            "answer": "Profectus BioSciences focuses on developing innovative vaccines and immunotherapies for infectious diseases and cancer."
        },
        {
            "question": "Who is the CEO of Profectus BioSciences?",
            "answer": "Dr. John Doe is the CEO of Profectus BioSciences, Inc."
        },
        {
            "question": "Where is Profectus BioSciences headquartered?",
            "answer": "Profectus BioSciences is headquartered in Baltimore, Maryland, USA."
        },
        {
            "question": "What are Profectus BioSciences' main products?",
            "answer": "Profectus BioSciences' main products include vaccines for HIV and other infectious diseases, as well as cancer immunotherapies."
        },
        {
            "question": "When was Profectus BioSciences founded?",
            "answer": "Profectus BioSciences was founded in 2002."
        }
    ],
    "competitors": [
        "MRNA",
        "NVAX",
        "BNTX",
        "REGN"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "VRTX",
        "ABBV"
    ]
}